Dae Seog Heo

23.3k total citations · 3 hit papers
472 papers, 17.9k citations indexed

About

Dae Seog Heo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Dae Seog Heo has authored 472 papers receiving a total of 17.9k indexed citations (citations by other indexed papers that have themselves been cited), including 266 papers in Oncology, 183 papers in Pulmonary and Respiratory Medicine and 70 papers in Pathology and Forensic Medicine. Recurrent topics in Dae Seog Heo's work include Lung Cancer Treatments and Mutations (120 papers), Lung Cancer Research Studies (70 papers) and Palliative Care and End-of-Life Issues (59 papers). Dae Seog Heo is often cited by papers focused on Lung Cancer Treatments and Mutations (120 papers), Lung Cancer Research Studies (70 papers) and Palliative Care and End-of-Life Issues (59 papers). Dae Seog Heo collaborates with scholars based in South Korea, United States and Ethiopia. Dae Seog Heo's co-authors include Tae Min Kim, Dong‐Wan Kim, Bhumsuk Keam, Se‐Hoon Lee, Yung‐Jue Bang, Yoon Kyung Jeon, Doo Hyun Chung, Noe Kyeong Kim, Seock‐Ah Im and Tae‐You Kim and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Dae Seog Heo

464 papers receiving 17.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

2012 776 citations Dae Seog Heo et al. profile →
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 656 citations Sae‐Won Han, Tae‐You Kim et al. profile →
Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

2004 609 citations Tae‐You Kim, Dae Seog Heo et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Dae Seog Heo

Since Specialization

Citations

This map shows the geographic impact of Dae Seog Heo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dae Seog Heo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dae Seog Heo more than expected).

Fields of papers citing papers by Dae Seog Heo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dae Seog Heo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dae Seog Heo. The network helps show where Dae Seog Heo may publish in the future.

Co-authorship network of co-authors of Dae Seog Heo

This figure shows the co-authorship network connecting the top 25 collaborators of Dae Seog Heo. A scholar is included among the top collaborators of Dae Seog Heo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dae Seog Heo. Dae Seog Heo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hospice-Palliative Medicine as a Model of Value-Based Healthcare 2022 ·Journal of Korean Medical Science ·Dae Seog Heo, Shin Hye Yoo, Bhumsuk Keam, (unknown), In‐Sun Choi, (unknown)	5
2	Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer 2021 ·Thoracic Cancer ·Eun Hee Jung, (unknown), Se Hyun Kim, Koung Jin Suh, Yu Jung Kim, Ju Hyun Lee, Jin‐Haeng Chung, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo, Jong Seok Lee	12
3	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines 2020 ·Journal for ImmunoTherapy of Cancer ·Ji‐Eun Park, Seong‐Eun Kim, Bhumsuk Keam, (unknown), Soyeon Kim, Miso Kim, Tae Min Kim, Junsang Doh, Dong‐Wan Kim, Dae Seog Heo	72
4	Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07 2020 ·Thoracic Cancer ·Miso Kim, Bhumsuk Keam, Chan‐Young Ock, Se Hyun Kim, Yu Jung Kim, Sun Min Lim, Jin‐Soo Kim, Tae Min Kim, Sook Hee Hong, Mi Sun Ahn, Seong Hoon Shin, Eun Joo Kang, Dong‐Wan Kim, (unknown), Jong‐Il Kim, Jong Seok Lee, Joo‐Hang Kim, Dae Seog Heo	19
5	Anthelmintics as Potential Anti-Cancer Drugs? 2020 ·Journal of Korean Medical Science ·Dae Seog Heo	3
6	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer 2018 ·Yonsei Medical Journal ·(unknown), Se Hyun Kim, Yu Jung Kim, Joo Hyun Lee, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong‐Wan Kim, Dae Seog Heo, Jin-Haeng Chung, Yoon Kyung Jeon, Jong Seok Lee	7
7	The fantasy of a new healthcare policy in Korea 2017 ·Journal of Korean Medical Association ·Dae Seog Heo	1
8	How to build successful hospice-palliative care systems in Korea 2017 ·Journal of Korean Medical Association ·Dae Seog Heo	1
9	Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors 2016 ·Cancer Immunology Research ·Yaewon Yang, (unknown), Tae Min Kim, Yong‐Oon Ahn, Hana Choi, (unknown), Bokyung Min, Jung Hyun Her, (unknown), Bhumsuk Keam, Se‐Hoon Lee, Dong‐Wan Kim, Yu Kyeong Hwang, Dae Seog Heo	128
10	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration 2016 ·Clinical Cancer Research ·Chan-Young Ock, Bhumsuk Keam, Sehui Kim, Ju‐Seog Lee, Miso Kim, Tae Min Kim, Yoon Kyung Jeon, Dong‐Wan Kim, Doo Hyun Chung, Dae Seog Heo	201
11	Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer 2015 ·Clinical Cancer Research ·(unknown), Tae Min Kim, Dong‐Wan Kim, Soyeon Kim, Bhumsuk Keam, Se‐Hoon Lee, Dae Seog Heo	99
12	Personalized cancer medicine: present status and future perspectives 2015 ·Journal of Korean Medical Association ·Dae Seog Heo	2
13	Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors 2014 ·Journal of Korean Medical Science ·Jeanny Kwon, Eui Kyu Chie, Kyubo Kim, Hak Jae Kim, Hong‐Gyun Wu, Il Han Kim, Do‐Youn Oh, Se‐Hoon Lee, Dong‐Wan Kim, Seock‐Ah Im, Tae‐You Kim, Dae Seog Heo, Yung‐Jue Bang, Sung Whan Ha	17
14	MicroRNA-146a Downregulates NFκB Activity via Targeting TRAF6 and Functions as a Tumor Suppressor Having Strong Prognostic Implications in NK/T Cell Lymphoma 2011 ·Clinical Cancer Research ·Jin Ho Paik, Ji-Young Jang, Yoon Kyung Jeon, Wook Youn Kim, Tae‐Min Kim, Dae Seog Heo, Jong Kyu Woo	152
15	A possible mechanism of impaired NK cytotoxicity in cancer patients: Down-regulation of DAP10 by TGF-β1 2011 ·Tumori ·(unknown), Kyung‐Mi Lee, Yong‐Oon Ahn, Beomseok Suh, Dae Seog Heo	18
16	Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group 2007 ·Haematologica ·David Christie, Elías Gracia, M. Gospodarowicz, G Martinelli, Katherine J. Deans, (unknown), (unknown), (unknown), Dae Seog Heo, David Porter, John Radford, H.H. Lucraft, (unknown), Nick Pavlakis, (unknown), (unknown), Carlo Visco, Barbara Pro	3
17	Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation 2006 ·Clinical Cancer Research ·Sae‐Won Han, Tae‐You Kim, Yoon Kyung Jeon, Pil Gyu Hwang, Seock‐Ah Im, Kyung-Hun Lee, Jee Hyun Kim, Dong‐Wan Kim, Dae Seog Heo, Noe Kyeong Kim, Doo Hyun Chung, Yung‐Jue Bang	196
18	Pharmacologic Management of Cancer Pain 2004 ·Journal of the Korean Medical Association ·Dae Seog Heo	28
19	Risk factors for ovarian metastasis following curative resection of gastric adenocarcinoma 1999 ·Cancer ·(unknown), Hark K. Kim, (unknown), Min S. Kim, Yong I. Kim, Dae Seog Heo, (unknown)	28
20	Risk factors for ovarian metastasis following curative resection of gastric adenocarcinoma 1999 ·Cancer ·(unknown), Hark K. Kim, (unknown), Min S. Kim, Yong I. Kim, Dae Seog Heo, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact